Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical results for patients with chronic lymphocytic leukemia (CLL). A treatment-induced rise in absolute lymphocyte count (ALC) has emerged as a class effect of kinase inhibitors in CLL and warrants further in...

Descripción completa

Detalles Bibliográficos
Autores principales: Herman, Sarah E. M., Niemann, Carsten U., Farooqui, Mohammed, Jones, Jade, Mustafa, Rashida Z., Lipsky, Andrew, Saba, Nakhle, Martyr, Sabrina, Soto, Susan, Valdez, Janet, Gyamfi, Jennifer A., Maric, Irina, Calvo, Katherine R., Pedersen, Lone B., Geisler, Christian H., Liu, Delong, Marti, Gerald E., Aue, Georg, Wiestner, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185271/
https://www.ncbi.nlm.nih.gov/pubmed/24699307
http://dx.doi.org/10.1038/leu.2014.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185271/
https://www.ncbi.nlm.nih.gov/pubmed/24699307
http://dx.doi.org/10.1038/leu.2014.122

Ejemplares similares